Non Small Cell Lung Cancer

Lorus Therapeutics Reports Results for Fiscal Year 2010 - DigitalJournal.com (press release)
( Tue, 31 Aug 2010 00:08:07 GMT+00:00 )

Lorus Therapeutics Reports Results for Fiscal Year 2010
DigitalJournal.com (press release)
Based on the approval of the IND by the FDA, trial with LOR-253 in advanced or metastatic solid tumors. cell lung cancers. In combination studies, IL-17E ...

and more »

STOCKS NEWS EUROPE-Transgene up on EU drug trial advice - Reuters
( Wed, 01 Sep 2010 10:24:53 GMT+00:00 )

STOCKS NEWS EUROPE-Transgene up on EU drug trial advice
Reuters
... that it can start late stage clinical trial testing on its non-small cell lung cancer drug, for which it has sealed a partnership with Novartis (NOVN. ...

and more »

Tests Uncover Asbestos in Sealant in Seven Virginia Beach Schools - eMaxHealth
( Mon, 30 Aug 2010 12:18:57 GMT+00:00 )

Tests Uncover Asbestos in Sealant in Seven Virginia Beach Schools
eMaxHealth
The fibrous minerals have been linked to lung cancer, asbestosis (lung scarring), and mesothelioma (cancer of the lung cavity lining. ...

and more »

Lung Cancer Survival Rates Improved Through Use of Individualised Chemotherapy - DG News
( Wed, 01 Sep 2010 20:30:54 GMT+00:00 )

Lung Cancer Survival Rates Improved Through Use of Individualised Chemotherapy
DG News
... analysed the usefulness of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) based on the histoculture drug response assay (HDRA). ...

and more »

Pfizer's Sutent Fails in Phase III Lung Cancer Trial - FDA news (subscription)
( Fri, 27 Aug 2010 16:12:47 GMT+00:00 )

Pfizer's Sutent Fails in Phase III Lung Cancer Trial
FDA news (subscription)
Pfizer's Sutent missed its primary endpoint of overall survival in a Phase III clinical trial of advanced non-small cell lung cancer (NSCLC) patients, ...

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with ... - TradersHuddle.com (press release)
( Fri, 27 Aug 2010 13:31:06 GMT+00:00 )

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with ...
TradersHuddle.com (press release)
... patients with advanced non-small cell lung cancer and in a Phase 1b clinical trial in combination with Erbitux and an irinotecan-containing treatment ...

and more »

JNM: PET/CT and SPECT/CT integral in cancer treatment planning - Health Imaging & IT
( Wed, 01 Sep 2010 16:32:16 GMT+00:00 )

JNM: PET/CT and SPECT/CT integral in cancer treatment planning
Health Imaging & IT
The fourth study investigated the role of 18F-FDG PET/CT for the early identification of response to therapy in patients with non-small cell lung cancer ...

and more »

Concordia Pharmaceuticals, Inc. Signs First Licensing Agreement with Ono ... - Benzinga
( Wed, 01 Sep 2010 12:55:38 GMT+00:00 )

Concordia Pharmaceuticals, Inc. Signs First Licensing Agreement with Ono ...
Benzinga
In certain types of cancers, such as pancreatic, non-small cell lung and colorectal cancers, the mutation of the Ras protein occurs frequently occurs and ...

and more »

Asuragen's Clinical Laboratory Launches KRAS and BRAF Mutation Testing - SunHerald.com
( Wed, 01 Sep 2010 13:12:09 GMT+00:00 )

Asuragen's Clinical Laboratory Launches KRAS and BRAF Mutation Testing
SunHerald.com
... non-small cell lung cancer, pancreatic cancer and others. Some mutations in the KRAS gene (about 40% of colorectal cancer patients) are associated with ...

and more »

Concordia Pharmaceuticals, Inc. Signs First Licensing Agreement with Ono ... - PharmaLive (press release) (subscription)
( Wed, 01 Sep 2010 13:06:26 GMT+00:00 )

Concordia Pharmaceuticals, Inc. Signs First Licensing Agreement with Ono ...
PharmaLive (press release) (subscription)
In certain types of cancers, such as pancreatic, non-small cell lung and colorectal cancers, the mutation of the Ras protein occurs frequently occurs and ...

and more »

New lung cancer drug funded in multi-product Roche agreement - New Zealand Doctor Online
( Thu, 02 Sep 2010 23:26:49 GMT+00:00 )

New lung cancer drug funded in multi-product Roche agreement
New Zealand Doctor Online
Erlotinib will be targeted to patients with advanced non small cell lung cancer who have already undergone chemotherapy. These patients would usually be ...

and more »

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with ... - Centre Daily Times
( Fri, 27 Aug 2010 14:23:55 GMT+00:00 )

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with ...
Centre Daily Times
... patients with advanced non-small cell lung cancer and in a Phase 1b clinical trial in combination with Erbitux and an irinotecan-containing treatment ...

and more »

FDA Committee Rejects Expanded Use of Jazz Drug on Abuse Concerns: Biotech's ... - Seeking Alpha (blog)
( Mon, 30 Aug 2010 12:44:16 GMT+00:00 )

FDA Committee Rejects Expanded Use of Jazz Drug on Abuse Concerns: Biotech's ...
Seeking Alpha (blog)
... significant improvement in overall survival of patients with previously treated advanced non-small cell lung cancer, the primary endpoint for the study. ...

Agennix AG Announces Data From Talactoferrin Randomized, Double-Blind, Placebo ... - Trading Markets (press release)
( Fri, 03 Sep 2010 08:02:15 GMT+00:00 )

Agennix AG Announces Data From Talactoferrin Randomized, Double-Blind, Placebo ...
Trading Markets (press release)
Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment ...

and more »

Court Report - Patent Docs (blog)
( Mon, 30 Aug 2010 03:44:11 GMT+00:00 )

Court Report
Patent Docs (blog)
... used to treat non-small cell lung cancer, pancreatic cancer, breast cancer, and ovarian cancer). View the complaint here. Schering Corp. et al v. ...

Lung cancer survival rates improved through use of individualized chemotherapy - The Pharma Letter
( Fri, 03 Sep 2010 09:45:15 GMT+00:00 )

Lung cancer survival rates improved through use of individualized chemotherapy
The Pharma Letter
... analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) based on the histoculture drug response assay (HDRA). ...

and more »

Complete the Form Below
and Unlock Your
Mobile Phone instantly!

Name

Email

Mobile/Cell Phone

How did you find us

designsurf.net		Home Contact Us